安科生物(300009) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 reached ¥734.10 million, representing a year-on-year increase of 17.28%[5] - The net profit attributable to shareholders for Q3 2023 was ¥258.06 million, up 3.29% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥247.60 million, reflecting a growth of 2.18% year-on-year[5] - The net profit for Q3 2023 was CNY 664,620,477.53, an increase of 9.8% compared to CNY 605,028,857.58 in Q3 2022[34] - The total revenue from operating activities was CNY 1,896,359,625.43, up from CNY 1,608,085,054.20 in the same period last year, reflecting a growth of 17.9%[34] - The total profit for Q3 2023 was CNY 767,775,513.10, which is a 9.5% increase from CNY 700,773,732.31 in Q3 2022[34] - The total comprehensive income attributable to the parent company was CNY 654,414,603.25, an increase from CNY 594,295,628.14 in Q3 2022, reflecting a growth of 10.1%[34] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥625.83 million, an increase of 41.71% compared to the previous year[5] - Operating cash flow net amount rose by 41.71% from CNY 441,638,832.27 to CNY 625,829,554.66, attributed to increased revenue and substantial cash receipts[12] - The cash flow from operating activities netted CNY 625,829,554.66, compared to CNY 441,638,832.27 in Q3 2022, marking a significant increase of 41.7%[34] - The cash flow from investing activities showed a net outflow of CNY 299,776,822.92, worsening from a net outflow of CNY 191,144,930.41 in Q3 2022[34] - The cash flow from financing activities resulted in a net outflow of CNY 405,805,654.59, compared to a net outflow of CNY 325,361,193.74 in the same quarter last year[34] - The company reported a decrease in cash flow from financing activities primarily due to increased dividend payments totaling CNY 411,076,008.00, compared to CNY 327,603,735.60 in Q3 2022[34] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4.59 billion, a 7.86% increase from the end of the previous year[5] - The equity attributable to shareholders at the end of Q3 2023 was ¥3.52 billion, up 9.80% from the previous year[5] - The total assets increased to CNY 4,591,233,321.82, compared to CNY 4,256,843,512.45 at the end of the previous year, marking a growth of 7.85%[28] - The company's total liabilities stood at CNY 867,532,181.42, up from CNY 855,166,124.71, indicating a slight increase of 0.43%[28] - The total liabilities as of September 30, 2023, were not explicitly stated but are essential for assessing the company's financial health[24] Research and Development - R&D expenses for the first nine months of 2023 totaled ¥152.94 million, marking a significant increase of 41.69% year-on-year[9] - Sales revenue from growth hormone products increased by 28.45% year-on-year, contributing to overall revenue growth[9] - Research and development expenses were CNY 152,939,567.06, reflecting a significant increase of 41.67% compared to CNY 107,940,546.47 in the previous year[29] - The company continues to focus on the development of new products, including targeted anti-tumor drugs, to enhance its market position[9] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 63,890[13] - The largest shareholder, Song Lihua, holds 26.55% of the shares, totaling 444,278,710 shares[13] Other Financial Metrics - The company implemented a new restricted stock incentive plan, incurring expenses of ¥18.10 million in Q3 2023, which impacted net profit growth[10] - Management expenses rose by 45.77% from CNY 90,494,279.32 to CNY 131,910,705.15, largely due to significant stock incentive plan expenses[12] - Investment income dropped by 121.90% from CNY 13,460,039.16 to CNY -2,947,595.00 due to significant losses recognized from long-term equity investments[12] - Other income decreased by 61.15% from CNY 29,905,315.10 to CNY 11,618,340.73, primarily due to reduced government subsidies received in the previous year[12] - The company recorded a credit impairment loss reversal of CNY 23 million in September 2022, which positively impacted the net profit growth rate year-on-year[40] - The company does not have any other items that meet the definition of non-recurring gains and losses[39] Audit and Adjustments - The third quarter report was not audited, indicating a need for caution in interpreting the financial data[38] - The net profit attributable to shareholders of the parent company for the period from January to September 2023 was adjusted to CNY 594,295,628.14, an increase of CNY 4,283.48 compared to the previous period[37] - The income tax expense for the period from January to September 2023 was adjusted to CNY 95,744,874.73, a decrease of CNY 11,635.41 from the previous period[37] - Deferred tax assets increased from CNY 40,278,512.04 on December 31, 2022, to CNY 41,796,206.86 on January 1, 2023, an adjustment of CNY 1,517,694.82[37] - Deferred tax liabilities rose from CNY 39,589,311.62 on December 31, 2022, to CNY 41,139,685.59 on January 1, 2023, reflecting an adjustment of CNY 1,550,373.97[37]